MA52411A - Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales - Google Patents

Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales

Info

Publication number
MA52411A
MA52411A MA052411A MA52411A MA52411A MA 52411 A MA52411 A MA 52411A MA 052411 A MA052411 A MA 052411A MA 52411 A MA52411 A MA 52411A MA 52411 A MA52411 A MA 52411A
Authority
MA
Morocco
Prior art keywords
medical uses
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
medical
Prior art date
Application number
MA052411A
Other languages
English (en)
Other versions
MA52411B1 (fr
Inventor
Ludwig Paul Cooymans
Werner Constant Johan Embrechts
Jérôme Émile Georges Guillemont
Tim Hugo Maria Jonckers
Gowan David Craig Mc
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA52411A publication Critical patent/MA52411A/fr
Publication of MA52411B1 publication Critical patent/MA52411B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
MA52411A 2018-03-01 2019-02-28 Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies MA52411B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18159583 2018-03-01
PCT/EP2019/054941 WO2019166532A1 (fr) 2018-03-01 2019-02-28 Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales

Publications (2)

Publication Number Publication Date
MA52411A true MA52411A (fr) 2021-01-06
MA52411B1 MA52411B1 (fr) 2022-12-30

Family

ID=61557126

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52411A MA52411B1 (fr) 2018-03-01 2019-02-28 Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies

Country Status (30)

Country Link
US (2) US11597704B2 (fr)
EP (2) EP3759083B1 (fr)
JP (1) JP2021514981A (fr)
KR (1) KR20200128394A (fr)
CN (1) CN111868040A (fr)
AR (1) AR114420A1 (fr)
AU (1) AU2019226342B2 (fr)
BR (1) BR112020017702A2 (fr)
CA (1) CA3091076A1 (fr)
CL (3) CL2020002253A1 (fr)
DK (1) DK3759083T3 (fr)
EA (1) EA202092052A1 (fr)
ES (1) ES2923579T3 (fr)
HR (1) HRP20220781T1 (fr)
HU (1) HUE059149T2 (fr)
IL (2) IL305388A (fr)
JO (1) JOP20200208A1 (fr)
LT (1) LT3759083T (fr)
MA (1) MA52411B1 (fr)
MD (1) MD3759083T2 (fr)
MX (2) MX2020009071A (fr)
PH (1) PH12020551345A1 (fr)
PL (1) PL3759083T3 (fr)
PT (1) PT3759083T (fr)
RS (1) RS63401B1 (fr)
SG (1) SG11202008293YA (fr)
SI (1) SI3759083T1 (fr)
TW (1) TW201945003A (fr)
UA (1) UA127590C2 (fr)
WO (1) WO2019166532A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027350A2 (fr) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Thérapie par interférence arn pour l'infection par le virus de l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3911416A1 (fr) 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Quinazolines substituées utilisées en tant que modulateurs de nlrp3, destinées à être utilisées dans le traitement du cancer
WO2020255039A1 (fr) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de quinazoline
AU2020333708C1 (en) * 2019-08-19 2024-02-22 Shanghai Zhimeng Biopharma Inc. 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof
CN114555565B (zh) * 2019-12-13 2024-03-05 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
US20230058425A1 (en) * 2020-01-02 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of pyridopyrimidine derivative and preparation method thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012964A (en) 1958-06-24 1961-12-12 Universal Oil Prod Co Hydrocarbon oil composition
US3022077A (en) 1958-09-15 1962-02-20 Doonan William Arrowhead construction
JP2610889B2 (ja) 1987-09-03 1997-05-14 日本臓器製薬株式会社 新規架橋アデニン誘導体
US6028076A (en) 1996-07-03 2000-02-22 Japan Energy Corporation Purine derivative
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
WO1998014448A1 (fr) 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
EP1035123B1 (fr) 1997-11-28 2003-08-20 Sumitomo Pharmaceuticals Company, Limited Nouveaux composes heterocycliques
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999041253A1 (fr) 1998-02-17 1999-08-19 Tularik Inc. Antiviraux derives de pyrimidine
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4315300B2 (ja) 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
CA2341707C (fr) 1998-08-27 2010-02-16 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrimidine
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
WO2002088079A2 (fr) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
EP1552842A1 (fr) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Derives bicycliques de pyrimidine
BR0314761A (pt) 2002-09-27 2005-07-26 Sumitomo Pharma Composto de adenina e seu uso
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
KR20060016817A (ko) 2003-06-20 2006-02-22 콜리 파마슈티칼 게엠베하 소분자 톨-유사 수용체 (ｔｌｒ) 길항제
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
WO2005092892A1 (fr) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. Compose 8-oxoadenine
WO2005092893A1 (fr) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. Compose 8-oxoadenine 9-substitue
WO2007084413A2 (fr) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Procedes de traitement de l’hepatite c
EP1797050B1 (fr) 2004-08-10 2013-10-23 Janssen Pharmaceutica NV Dérivés de 1,2,4-triazin-6-one destinés à inhiber le hiv
AU2005304040B2 (en) 2004-11-09 2009-04-23 F. Hoffmann-La Roche Ag Aminoquinazolines compounds
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
BRPI0611435A2 (pt) 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
MX2007013715A (es) 2005-05-05 2008-01-28 Ardea Biosciences Inc Diaril-purinas, azapurinas y deazapurinas como inhibidores no nucleosidos de transcriptasa inversa para el tratamiento del virus de inmunodeficiencia humana.
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
JP4850911B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007056208A2 (fr) 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation de ceux-ci
WO2007063934A1 (fr) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation Compose heterocyclique alicyclique
BRPI0707945A2 (pt) 2006-02-17 2011-05-17 Pfizer Ltd derivados de 3-deazapurina como modulares de tlr7
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
JP5500990B2 (ja) 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
EP2121707B1 (fr) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Indoles antiviraux
PT2510946E (pt) 2007-02-07 2015-11-23 Univ California Conjugados de agonistas sintéticos de tlr e suas utilizações
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
JP5480637B2 (ja) 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
WO2008114819A1 (fr) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. Nouveau composé d'adénine
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
EP2152674B1 (fr) 2007-05-22 2011-08-03 Boehringer Ingelheim International GmbH Inhibiteurs de benzimidazolone chymase
KR101561710B1 (ko) 2007-06-29 2015-10-19 길리애드 사이언시즈, 인코포레이티드 퓨린 유도체 및 그것의 톨 유사 수용체 7의 조절 인자로서 용도
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
MX2010002336A (es) 2007-08-28 2010-03-25 Irm Llc Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
WO2009030998A1 (fr) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés pyrimidine utilisés comme agonistes du récepteur de type toll (tlr)
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
EP2238142B1 (fr) 2007-12-24 2012-07-04 Janssen R&D Ireland Indoles macrocycliques en tant qu'inhibiteurs du virus de l'hépatite c
EP2259788A4 (fr) 2008-02-07 2011-03-16 Univ California Traitement des maladies de la vessie avec un activateur de tlr7
WO2009134624A1 (fr) 2008-04-28 2009-11-05 Merck & Co., Inc. Inhibiteurs de la protéase hcv ns3
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
DK2313111T3 (da) 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf
CA2760766A1 (fr) 2009-05-21 2010-11-25 Nicholas James Bennett Nouveaux derives pyrimidines et leur utilisation dans le traitement d'un cancer et autres maladies
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
IN2012DN02984A (fr) 2009-10-22 2015-07-31 Gilead Sciences Inc
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012045089A2 (fr) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Méthodes de traitement de maladies allergiques
WO2012066335A1 (fr) 2010-11-19 2012-05-24 Astrazeneca Ab Composés phénol en tant qu'agonistes du récepteur 7 de type toll
WO2012067269A1 (fr) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies
KR102058946B1 (ko) 2011-04-08 2019-12-24 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
BR112013029537B1 (pt) * 2011-05-18 2020-06-30 Janssen Sciences Ireland Uc derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende
IN2014MN00862A (fr) 2011-11-09 2015-04-17 Janssen R & D Ireland
BR112014019699B1 (pt) 2012-02-08 2021-12-07 Janssen Sciences Ireland Uc Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
EP2841428B1 (fr) 2012-04-24 2018-08-22 Vertex Pharmaceuticals Incorporated Inhibiteurs d'adn pk
UA113651C2 (xx) 2012-07-13 2017-02-27 Макроциклічні пурини для лікування вірусних інфекцій
EA029266B1 (ru) 2012-08-10 2018-02-28 Янссен Сайенсиз Айрлэнд Юси Алкилпиримидиновые производные для лечения вирусных инфекций
TW201920090A (zh) 2012-08-28 2019-06-01 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基－芳醯胺類及其做為治療ｂ型肝炎之醫藥劑的用途
EP2712866A1 (fr) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) Dérivés de 1,2,4-triazine pour le traitement d'infections virales
JP6283033B2 (ja) 2012-10-05 2018-02-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
PL2925729T3 (pl) 2012-11-16 2018-04-30 Janssen Sciences Ireland Uc Heterocykliczne podstawione pochodne 2-amino-chinazoliny do leczenia infekcji wirusowych
BR112015020118B1 (pt) 2013-02-21 2022-02-22 Janssen Sciences Ireland Uc Derivados de 2-aminopirimidina para o tratamento de infecções virais, composição farmacêutica e uso
HUE031908T2 (en) 2013-03-29 2017-08-28 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US10377738B2 (en) 2013-05-24 2019-08-13 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
BR112015032546B1 (pt) * 2013-06-27 2022-05-17 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
EA036162B1 (ru) * 2013-07-30 2020-10-08 Янссен Сайенсиз Айрлэнд Юси Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций
EP3166938A4 (fr) 2014-07-11 2018-01-17 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
CU20180011A7 (es) 2015-03-04 2018-06-05 Gilead Sciences Inc Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
AR107633A1 (es) 2016-02-19 2018-05-16 Hoffmann La Roche Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
CA3021068A1 (fr) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Associations et methodes comprenant un inhibiteur d'ensemble capside
MA45539A (fr) * 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
CA3035346A1 (fr) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. Composes modulateurs du recepteur de type toll

Also Published As

Publication number Publication date
UA127590C2 (uk) 2023-10-25
AR114420A1 (es) 2020-09-02
CL2021001753A1 (es) 2021-12-17
PT3759083T (pt) 2022-07-05
PH12020551345A1 (en) 2021-09-06
EP4059924A1 (fr) 2022-09-21
EA202092052A1 (ru) 2020-12-07
JP2021514981A (ja) 2021-06-17
IL305388A (en) 2023-10-01
AU2019226342A1 (en) 2020-08-13
SG11202008293YA (en) 2020-09-29
US20210040046A1 (en) 2021-02-11
KR20200128394A (ko) 2020-11-12
BR112020017702A2 (pt) 2020-12-22
US20230278964A1 (en) 2023-09-07
DK3759083T3 (da) 2022-08-01
CN111868040A (zh) 2020-10-30
AU2019226342B2 (en) 2024-02-15
CL2020002253A1 (es) 2021-01-15
EP3759083B1 (fr) 2022-05-04
MX2020009071A (es) 2020-10-08
IL276952B1 (en) 2023-10-01
JOP20200208A1 (ar) 2020-08-30
WO2019166532A1 (fr) 2019-09-06
IL276952A (en) 2020-10-29
CL2022000125A1 (es) 2022-10-07
ES2923579T3 (es) 2022-09-28
CA3091076A1 (fr) 2019-09-06
IL276952B2 (en) 2024-02-01
HUE059149T2 (hu) 2022-10-28
EP3759083A1 (fr) 2021-01-06
TW201945003A (zh) 2019-12-01
SI3759083T1 (sl) 2022-08-31
LT3759083T (lt) 2022-07-11
PL3759083T3 (pl) 2022-08-29
MA52411B1 (fr) 2022-12-30
RS63401B1 (sr) 2022-08-31
HRP20220781T1 (hr) 2022-09-30
US11597704B2 (en) 2023-03-07
MX2023001803A (es) 2023-03-10
MD3759083T2 (ro) 2022-09-30

Similar Documents

Publication Publication Date Title
MA52483A (fr) Dérivés de gip et leurs utilisations
MA52411A (fr) Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales
MA49952A (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
DK4015003T3 (da) Forbedret antistof-oligonukleotid-konjugat
MA50618A (fr) Polyrhérapies et leurs utilisations
MA52426A (fr) Conjugués d'il-15 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA42599A (fr) Dérivés de triazole, leurs intermédiaires et leur utilisation comme fongicides
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA50173A (fr) Composés activateurs de bisamide sarcomère et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
MA50413A (fr) Dérivés de benzimidazole et leurs utilisations
MA54051A (fr) Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations
MA55083A (fr) Polyribonucléotides et leurs utilisations cosmétiques
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations
MA54521A (fr) Dérivés d'oxopyridine substitués
MA52365A (fr) Composés et leurs utilisations
MA51840A (fr) Modulateurs de somatostatine et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
MA52434A (fr) Amphiphiles cpg et leurs utilisations
MA55385A (fr) Composés et leurs utilisations
MA52977A (fr) Composés de cyanotriazole et leurs utilisations